Patients Bring Rare Disease Priorities to FDA’s Framework Discussion

October 28, 2026

Patients and other stakeholders in rare disease treatment shared their perspectives on drug development and approval with agency leaders at a public meeting convened by the FDA and the Reagan-Udall Foundation for the FDA at the FDA’s White Oak campus in Silver Spring, Maryland, on October 28.

“The most compelling contributions showed why patients need a voice long before a treatment reaches an approval decision,” said Tagline’s principal and founder Tara Rabin, who was in attendance.

Public Comments

After opening remarks from senior FDA leaders Diamantas, Mikhail and Davis, the meeting turned to public comments from patients, caregivers, advocates, researchers and industry representatives, including Monica Weldon, whose daughter was the sixth child in the world diagnosed with the ultra-rare genetic disease SYNGAP1 in 2012. She went on to found a research organization for the condition and helped build the foundation for a U.S. clinical trial. Her account captured a reality familiar to many rare disease families: when little is known about a condition, parents often become the people advocating, organizing research, and gathering the evidence that informs early development of future treatments.

The high stakes in rare disease also surfaced in a forceful presentation by Dr. Tracy Mayne, senior vice president of Regulatory and Life Sciences Research at Slipstream Life Sciences, about the gap between the research models most relied upon by regulators and the types of trials that patients can realistically enter. He spoke about the difficulty of enrolling enough patients in glioblastoma trials and argued for greater use of real-world evidence and external controls. Moments like that gave the meeting its urgency, but patients and caregivers also supplied something equally important: a precise account of what benefit would mean for them.

A speaker living with the neurodegenerative disease ALS addressed the meeting through a cloned voice, having lost the ability to speak. “Time is not an abstract consideration,” the speaker said. Slowing decline or preserving a function may matter profoundly even when a treatment cannot restore what has already been lost. A narcolepsy advocate urged researchers to look beyond symptom control to whether people with rare diseases can stay in school, work, and care for their families. A father described how preserving his daughter’s arm strength could help her drive her wheelchair, protect her breathing, and get through a school day.

Key Takeaways

The clear message from the meeting was that these questions of what successful treatment would mean for patients should be asked at the beginning of development, not the end. Patient and caregiver input can help researchers and developers identify meaningful outcomes, reveal which trial requirements make participation impossible, and put potential benefits and risks in context. That input can help researchers collect evidence that answers the real questions patients face. One advocate asked bluntly that patients and caregivers be involved “while the decision is actually still open,” and that people outside established advocacy organizations be consulted. Their insights should be reflected in deliberations about endpoints, eligibility, visit schedules, and evidence plans. Contributors also deserve an explanation of what changed as a result of their input.

Tagline’s Analysis

“Tagline can help clients work with patient advocacy organizations at that earlier stage,” said Tara. “That means building relationships before study plans are fixed, listening across a community whose experiences may differ widely, and translating what patients say into decisions that development and regulatory teams can use.”

As one mother told the meeting, patient voice should help shape “the evidence we collect, the outcomes we measure, and the decisions we make.” For rare diseases, early engagement makes the path to approval more responsive to the lives a treatment is meant to improve.

Back to All News

Stay in the Know with
Our Latest Insights

Sign up for Tagline’s Newsletter, a digest of regulatory, policy, and communications developments shaping the industries we serve. We promise not to spam you! Our aim is to publish a quarterly newsletter with special features once in a while.

Sign Up